Stock Price
1.29
Daily Change
-4.44%
Yearly
-53.93%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amgen 203.47 2.38 1.18% -8.36%
Arena Pharmaceuticals 54.96 -2.46 -4.28% -16.56%
AstraZeneca 8,367.00 -44.00 -0.52% 7.20%
Baxter International 76.03 -0.26 -0.34% -0.05%
Biogen 236.11 -6.79 -2.80% -1.69%
Bioline Rx 2.57 -0.03 -1.15% 12.23%
Bristol-Myers Squibb 54.64 -1.89 -3.34% -12.44%
Corcept Therapeutics 21.12 -0.37 -1.72% -6.71%
Curis 4.84 -0.26 -5.10% 233.79%
Eleven Biotherapeutics 1.07 -0.01 -0.93% -13.71%
Five Prime Therapeutics 38.00 0 0% 1,339.39%
Gilead Sciences 70.65 0.38 0.54% 16.45%
GlaxoSmithKline 1,525.00 14.20 0.94% 11.31%
Intercept Pharmaceuticals 16.43 -0.67 -3.92% -53.73%
Immunogen 4.75 -0.06 -1.25% -12.84%
Incyte Corp 70.37 1.99 2.91% -16.76%
Ionis Pharmaceuticals 29.05 -0.71 -2.39% -43.18%
J&J 159.75 0.55 0.35% 10.42%
Karyopharm Therapeutics 6.85 -0.42 -5.78% -59.68%
Merck & Co 74.89 -4.27 -5.39% -6.84%
Novartis 74.24 -0.48 -0.64% -9.76%
Pfizer 52.40 -1.60 -2.96% 36.78%
PTC Therapeutics 36.89 -1.17 -3.07% -41.04%
Regeneron Pharmaceuticals 654.40 11.05 1.72% 26.81%
Roche Holding 357.50 -1.10 -0.31% 19.55%
Sangamo BioSciences 8.22 -0.23 -2.72% -17.72%
TG Therapeutics 23.36 -0.62 -2.59% -20.38%
Verastem 2.59 -0.09 -3.36% 28.86%
Intrexon 3.78 -0.08 -2.07% -52.27%
Ziopharm Oncology 1.29 -0.06 -4.44% -53.93%

Indexes Price Day Year
US2000 2242 -3.96 -0.18% 23.20%
NASDAQ 15783 291.18 1.88% 29.38%

Ziopharm Oncology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.